Treatment of tumour-bearing mice with IF7C(RR)-SN38

IF7C(RR)-SN38 was injected intravenously through the tail vein into tumour-bearing mice once photon number of C6-Luc brain tumour reached 5 × 10⁴, which usually occurred after 2 weeks. IF7C(RR)-SN38 (142 μg or 0.0567 μmoles) dissolved in 10 μl dimethylsulfoxide (DMSO) diluted with 100 μl of 50% Cremophore EL in ethanol plus 90 μl PBS was injected intravenously through the tail vein. As the average body weight of a mouse was 18 g, IF7C(RR)-SN38 dose per injection was 3.15 μmoles/kg. For B16-Luc brain tumours, IF7C(RR)-SN38 formulated with Cremophore EL was used at the dosage 7.0 μmoles/kg. Irinotecan (CPT-11), a water soluble SN38 prodrug, was dissolved in PBS and intravenously injected into mice at 50 μmoles /kg. In another set of experiments, brain tumour-bearing mice were treated with IF7C(RR)-SN38 (100 μg or 0.0412 μmoles) dissolved in 10 μl DMSO followed by dilution with 100 μl 10% Solutol HS15 in water. In that case, drug dosage was 2.5 μmoles/kg. Similarly formulated C(RR)-SN38 served as control.